Provided by Tiger Trade Technology Pte. Ltd.

Agios Pharmaceuticals

33.09
-0.5400-1.61%
Post-market: 33.090.00000.00%19:30 EDT
Volume:577.55K
Turnover:19.22M
Market Cap:1.97B
PE:-4.72
High:34.09
Open:33.62
Low:32.95
Close:33.63
52wk High:46.00
52wk Low:22.24
Shares:59.47M
Float Shares:50.09M
Volume Ratio:0.51
T/O Rate:1.15%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-7.0075
EPS(LYR):-7.1203
ROE:-34.34%
ROA:-22.24%
PB:1.92
PE(LYR):-4.65

Loading ...

Agios Pharmaceuticals price target lowered to $52 from $54 at H.C. Wainwright

TIPRANKS
·
Jul 21

U.S. Stocks on the Move-utz Brands, Tutor Perini, Tripadvisor

Reuters
·
Jul 21

U.S. Stocks on the Move-3m, Gold Miners, Hasbro

Reuters
·
Jul 21

Top Premarket Decliners

MT Newswires Live
·
Jul 21

Agios Falls After Scrapping Experimental Sickle Cell Disease Drug

Reuters
·
Jul 21

Agios Pharmaceuticals Shares Down 12.6% Premarket as it Discontinues Sickle Cell Disease Drug Development

THOMSON REUTERS
·
Jul 21

Agios Pharma to Discontinue Sickle Cell Disease Treatment Development

Reuters
·
Jul 21

Agios Posts Phase 2 Tebapivat Sickle Cell Trial Update Press Release

Reuters
·
Jul 21

Agios Pharmaceuticals - Will not Advance Tebapivat in Sickle Cell Disease

THOMSON REUTERS
·
Jul 21

Agios Pharmaceuticals - FDA Priority Review for Mitapivat in Sickle Cell Disease; Pdufa Date November 1, 2026

THOMSON REUTERS
·
Jul 21

Agios Pharmaceuticals - Tebapivat Safety Consistent with Prior Sickle Cell Disease Trials

THOMSON REUTERS
·
Jul 21

Agios Pharmaceuticals - Primary Endpoint Achieved by up to 47.1% in Tebapivat Arms; 33.3% in Placebo Arm

THOMSON REUTERS
·
Jul 21

Agios Provides Update on Phase 2 Trial of Tebapivat in Sickle Cell Disease

THOMSON REUTERS
·
Jul 21

The Bull Case For Agios Pharmaceuticals (AGIO) Could Change Following FDA Priority Review For Mitapivat In Sickle Cell

Simply Wall St.
·
Jul 19

H.C. Wainwright Remains a Buy on Agios Pharma (AGIO)

TIPRANKS
·
Jul 13

Analysts Offer Insights on Healthcare Companies: Oncology Institute (TOI) and Agios Pharma (AGIO)

TIPRANKS
·
Jul 07

H.C. Wainwright sees FDA Priority Review as positive signal for Agios’ mitapivat

TIPRANKS
·
Jul 07

Moderna, TG Therapeutics, Agios Pharmaceuticals Q2 Results May Face Increased Scrutiny, BofA Says

MT Newswires Live
·
Jul 07

Agios Pharmaceuticals Shares Rise 12.4% After US FDA Grants Priority Review to Sickle Cell Disease Drug

THOMSON REUTERS
·
Jul 07

Agios Pharmaceuticals rises 12.9%

TIPRANKS
·
Jul 07